Replies to post #134299 on Biotech Values

[mcbio]

Makes sense as it seems more logical to use an mTor inhibitor after Sutent instead of another (although different) TKI.

Have there been trials, or do you know if there are any ongoing trials or plans for trials, to combine an mTor inhibitor with Sutent or other TKIs instead of using one after the other in these types of patient populations?